晚期子宫内膜癌-话题@MedSci

#晚期子宫内膜癌#

8篇内容 | 821人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2159952, encodeId=348f2159952a7, content=<a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠单抗#</a>加化疗治疗<a href='/topic/show?id=502f5982060' target=_blank style='color:#2F92EE;'>#晚期子宫内膜癌#</a>，效果相当不错!!<a href='/topic/show?id=942b4516096' target=_blank style='color:#2F92EE;'>#子宫内膜癌#</a>, objectTitle=NEJM:帕博利珠单抗加化疗治疗晚期子宫内膜癌, objectType=article, longId=786740, objectId=8c67e867409f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230814/1691987464614_6145188.jpg, objectUrl=/article/show_article.do?id=8c67e867409f, replyNumber=0, likeNumber=36, createdTime=2023-09-27, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8c67e867409f, moduleTitle=NEJM:帕博利珠单抗加化疗治疗晚期子宫内膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c67e867409f)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1640748, encodeId=287d1640e48e3, content=<a href='/topic/show?id=502f5982060' target=_blank style='color:#2F92EE;'>#晚期子宫内膜癌#</a>, objectTitle=J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效, objectType=article, longId=300936, objectId=cbcd3009360c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbcd3009360c, replyNumber=0, likeNumber=46, createdTime=2022-08-16, rootId=0, userName=12498b08m97暂无昵称, userId=718a22711194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbcd3009360c, moduleTitle=J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbcd3009360c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640746, encodeId=5fa91640e4660, content=<a href='/topic/show?id=502f5982060' target=_blank style='color:#2F92EE;'>#晚期子宫内膜癌#</a>, objectTitle=J Clin Oncol：派姆单抗治疗不稳定性高的晚期子宫内膜癌的疗效, objectType=article, longId=294803, objectId=6aaf29480333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aaf29480333, replyNumber=0, likeNumber=44, createdTime=2022-04-03, rootId=0, userName=12498b08m97暂无昵称, userId=718a22711194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aaf29480333, moduleTitle=J Clin Oncol：派姆单抗治疗不稳定性高的晚期子宫内膜癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aaf29480333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640747, encodeId=acf61640e470c, content=<a href='/topic/show?id=502f5982060' target=_blank style='color:#2F92EE;'>#晚期子宫内膜癌#</a>, objectTitle=NEJM：乐伐替尼加派姆单抗治疗晚期子宫内膜癌, objectType=article, longId=295126, objectId=f06e2951268b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f06e2951268b, replyNumber=0, likeNumber=37, createdTime=2022-07-23, rootId=0, userName=12498b08m97暂无昵称, userId=718a22711194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f06e2951268b, moduleTitle=NEJM：乐伐替尼加派姆单抗治疗晚期子宫内膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f06e2951268b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640745, encodeId=86f31640e452a, content=<a href='/topic/show?id=502f5982060' target=_blank style='color:#2F92EE;'>#晚期子宫内膜癌#</a>, objectTitle= AJOG：晚期子宫内膜癌是否有必要进行肿瘤细胞减灭术？, objectType=article, longId=211531, objectId=82d021153179, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82d021153179, replyNumber=0, likeNumber=39, createdTime=2021-09-17, rootId=0, userName=12498b08m97暂无昵称, userId=718a22711194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82d021153179, moduleTitle= AJOG：晚期子宫内膜癌是否有必要进行肿瘤细胞减灭术？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82d021153179)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640744, encodeId=e58a1640e441f, content=<a href='/topic/show?id=502f5982060' target=_blank style='color:#2F92EE;'>#晚期子宫内膜癌#</a>, objectTitle=lenvatinib联合KEYTRUDA（pembrolizumab）在晚期子宫内膜癌研究中获得积极结果, objectType=article, longId=190523, objectId=37e61905231f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37e61905231f, replyNumber=0, likeNumber=39, createdTime=2020-07-31, rootId=0, userName=12498b08m97暂无昵称, userId=718a22711194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37e61905231f, moduleTitle=lenvatinib联合KEYTRUDA（pembrolizumab）在晚期子宫内膜癌研究中获得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37e61905231f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640743, encodeId=32bd1640e4324, content=<a href='/topic/show?id=502f5982060' target=_blank style='color:#2F92EE;'>#晚期子宫内膜癌#</a>, objectTitle=NEJM：辅助化疗加放射治疗局部晚期子宫内膜癌, objectType=article, longId=168303, objectId=13e216830312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13e216830312, replyNumber=0, likeNumber=34, createdTime=2019-12-18, rootId=0, userName=12498b08m97暂无昵称, userId=718a22711194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13e216830312, moduleTitle=NEJM：辅助化疗加放射治疗局部晚期子宫内膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13e216830312)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1640742, encodeId=a7a01640e42f0, content=<a href='/topic/show?id=502f5982060' target=_blank style='color:#2F92EE;'>#晚期子宫内膜癌#</a>, objectTitle=JCO：地磷莫司治疗晚期子宫内膜癌是有效的，但毒副作用太大, objectType=article, longId=58171, objectId=6785581e140, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6785581e140, replyNumber=0, likeNumber=33, createdTime=2016-09-01, rootId=0, userName=12498b08m97暂无昵称, userId=718a22711194, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6785581e140, moduleTitle=JCO：地磷莫司治疗晚期子宫内膜癌是有效的，但毒副作用太大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6785581e140)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期子宫内膜癌

2020-05-29

(审核中...)

前往app查看评论内容

#帕博利珠单抗#加化疗治疗#晚期子宫内膜癌#，效果相当不错!!#子宫内膜癌#

NEJM:帕博利珠单抗加化疗治疗晚期子宫内膜癌

2023-09-27发表于上海

12498b08m97暂无昵称 (审核中...)

前往app查看评论内容

#晚期子宫内膜癌#

J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效

2022-08-16

12498b08m97暂无昵称 (审核中...)

前往app查看评论内容

#晚期子宫内膜癌#

J Clin Oncol：派姆单抗治疗不稳定性高的晚期子宫内膜癌的疗效

2022-04-03

12498b08m97暂无昵称 (审核中...)

前往app查看评论内容

#晚期子宫内膜癌#

NEJM：乐伐替尼加派姆单抗治疗晚期子宫内膜癌

2022-07-23

12498b08m97暂无昵称 (审核中...)

前往app查看评论内容

#晚期子宫内膜癌#

AJOG：晚期子宫内膜癌是否有必要进行肿瘤细胞减灭术？

2021-09-17

12498b08m97暂无昵称 (审核中...)

前往app查看评论内容

#晚期子宫内膜癌#

lenvatinib联合KEYTRUDA（pembrolizumab）在晚期子宫内膜癌研究中获得积极结果

2020-07-31

12498b08m97暂无昵称 (审核中...)

前往app查看评论内容

#晚期子宫内膜癌#

NEJM：辅助化疗加放射治疗局部晚期子宫内膜癌

2019-12-18

12498b08m97暂无昵称 (审核中...)

前往app查看评论内容

#晚期子宫内膜癌#

JCO：地磷莫司治疗晚期子宫内膜癌是有效的，但毒副作用太大

2016-09-01

科室
- - 订阅+
  - 更多科室
工具
服务